Table 1.
Baseline characteristics
| LiMAx® group (n = 76) | Control group (n = 72) | |
|---|---|---|
| Mean(s.d.) age (years) | 59·5(13·2) | 56·2(14·6) |
| Sex ratio (M : F) | 44 : 32 | 39 : 33 |
| Weight (kg) | n = 76 | n = 70 |
| Mean(s.d.) | 78·7(16·6) | 80·1(16·8) |
| Median (range) | 77 (53–142) | 80 (43–113) |
| Height (cm) | n = 76 | n = 70 |
| Mean(s.d.) | 170·6 (8·6) | 171·8 (9·0) |
| Median (range) | 171 (150–186) | 173 (150–189) |
| Indication for surgery | ||
| Hepatocellular carcinoma | 13 (17) | 8 (11) |
| Cholangiocelluar carcinoma | 9 (12) | 5 (7) |
| Liver metastasis, colorectal | 27 (36) | 34 (47) |
| Liver metastasis, melanoma | 3 (4) | 1 (1) |
| Adenoma (liver) | 4 (5) | 4 (6) |
| Focal nodular hyperplasia | 2 (3) | 3 (4) |
| Other | 7 (9) | 12 (17) |
| Other liver metastasis | 11 (14) | 5 (7) |
| Relevant concomitant disease | ||
| Chronic hepatitis B | 1 (1) | 1 (1) |
| Chronic hepatitis C | 0 (0) | 0 (0) |
| Non‐alcoholic steatohepatitis | 3 (4) | 1 (1) |
| Autoimmune hepatitis | 0 (0) | 0 (0) |
| Primary biliary cirrhosis | 0 (0) | 0 (0) |
| Primary sclerotic cholangitis | 0 (0) | 0 (0) |
| Liver cirrhosis | 0 (0) | 0 (0) |
| Hepatic steatosis | 14 (18) | 10 (14) |
| Previous surgery or therapy | ||
| Yes | 70 (92) | 69 (96) |
| No | 6 (8) | 3 (4) |
| Intake of medication 30 days before inclusion | ||
| Yes | 57 (75) | 55 (76) |
| No | 19 (25) | 17 (24) |
Values in parentheses are percentages unless indicated otherwise.